Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Siteng Fang"'
Autor:
Siteng Fang, Brittany M. Brems, Emmanuel O. Olawode, Jared T. Miller, Tracy A. Brooks, L. Nathan Tumey
Publikováno v:
Molecular Pharmaceutics. 19:3228-3241
Traditional antibody-drug conjugate (ADC) technology has employed tumor-targeting antibodies to selectively deliver ultrapotent cytotoxins to tumor tissue. While this technology has been highly successful, resulting in the FDA approval of over 10 ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5052939e1617b4c62875911f007b1f23
https://doi.org/10.1021/acs.molpharmaceut.2c00392
https://doi.org/10.1021/acs.molpharmaceut.2c00392
Autor:
Courtney P. Jackson, Siteng Fang, Samantha R. Benjamin, Tchilabalo Alayi, Yetrib Hathout, Sarah M. Gillen, Jillian P. Handel, Brittany M. Brems, Justin M. Howe, L. Nathan Tumey
Publikováno v:
Bioorganicmedicinal chemistry letters. 75
In spite of their value in prodrug applications, the use of esters in antibody-drug-conjugate (ADC) payloads and linkers has generally been avoided due to the ubiquitous and promiscuous nature of human esterases. ADCs generally have a long circulatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26da8a60c97bc30ec714f300593375d7
https://pubmed.ncbi.nlm.nih.gov/36058468
https://pubmed.ncbi.nlm.nih.gov/36058468
Publikováno v:
Bioconjugate chemistry. 32(4)
Over the past two decades, antibody drug conjugates (ADCs) and small molecule drug conjugates (SMDCs) have widely employed valine-citruline and related cathepsin-cleavable linkers due to their stability in plasma and their rapid cleavage by lysosomal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7504dbc43a0578d5e97f72ae50177474
https://pubmed.ncbi.nlm.nih.gov/33788548
https://pubmed.ncbi.nlm.nih.gov/33788548
Autor:
Zhongyuan Guo, L. Nathan Tumey, Siteng Fang, Courtney P. Jackson, Dane P. Carlson, Samantha R. Benjamin
Publikováno v:
Molecular pharmaceutics. 16(6)
Site-specific conjugation technology frequently relies on antibody engineering to incorporate rare or non-natural amino acids into the primary sequence of the protein. However, when the primary sequence is unknown or when antibody engineering is not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a168c0a088a50e2705bef23e29d73319
https://pubmed.ncbi.nlm.nih.gov/31067063
https://pubmed.ncbi.nlm.nih.gov/31067063